Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid A Mayer

Showing results (11-20 of 147) with videos related to

Pageof 15
Sort By:
Drugs|September 7, 2020
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast CancerSara E Nunnery, Ingrid A Mayer
Current Treatment Options in Oncology|September 16, 2011
Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancerVandana G Abramson, Ingrid A Mayer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?Ingrid A Mayer, Carlos L Arteaga
Current Breast Cancer Reports|June 21, 2021
Novel Agents for the Management of Endocrine Resistant Breast CancerSonya Reid-Lawrence, Ingrid A Mayer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Does lapatinib work against HER2-negative breast cancers?Ingrid A Mayer, Carlos L Arteaga
Therapeutic Advances in Medical Oncology|May 17, 2012
Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancerVandana G Abramson, Ingrid A Mayer
Annual Review of Medicine|October 17, 2015
The PI3K/AKT Pathway as a Target for Cancer TreatmentIngrid A Mayer, Carlos L Arteaga
The New England Journal of Medicine|June 13, 2019
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. ReplyAditya Bardia, Ingrid A Mayer, Kevin Kalinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Resistance to Trastuzumab in Breast CancerPaula R Pohlmann, Ingrid A Mayer, Ray Mernaugh
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer?Valerie M Jansen, Ingrid A Mayer, Carlos L Arteaga
Pageof 15

Showing results (11-20 of 147) with videos related to

Sort By:
Pageof 15
Drugs|September 7, 2020
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast CancerSara E Nunnery, Ingrid A Mayer
Current Treatment Options in Oncology|September 16, 2011
Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancerVandana G Abramson, Ingrid A Mayer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?Ingrid A Mayer, Carlos L Arteaga
Current Breast Cancer Reports|June 21, 2021
Novel Agents for the Management of Endocrine Resistant Breast CancerSonya Reid-Lawrence, Ingrid A Mayer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Does lapatinib work against HER2-negative breast cancers?Ingrid A Mayer, Carlos L Arteaga
Therapeutic Advances in Medical Oncology|May 17, 2012
Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancerVandana G Abramson, Ingrid A Mayer
Annual Review of Medicine|October 17, 2015
The PI3K/AKT Pathway as a Target for Cancer TreatmentIngrid A Mayer, Carlos L Arteaga
The New England Journal of Medicine|June 13, 2019
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. ReplyAditya Bardia, Ingrid A Mayer, Kevin Kalinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Resistance to Trastuzumab in Breast CancerPaula R Pohlmann, Ingrid A Mayer, Ray Mernaugh
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer?Valerie M Jansen, Ingrid A Mayer, Carlos L Arteaga
Pageof 15